UNSPSC 51292012: Fluoxetine hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01K63SUP8D, chemically known as (+) or (-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine but generally known as fluoxetine, which bears US NIH Compound Identifier 3386. European Medicines Agency schedules Fluoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07723MIG.

UNSPSC 51292012 Fluoxetine hydrochloride (Commodity) covers a specific antidepressant medication, but state and local procurement activity under this code shows little alignment with the pharmaceutical ingredient itself. Recent solicitations tagged to the code instead reflect broader pharmaceutical procurement frameworks: multi-state cooperative purchasing agreements for generic drugs and OTC products through authorized wholesalers, direct-to-manufacturer prescription programs, and naloxone procurement for community health initiatives. The actual work being solicited involves establishing supply contracts and pricing arrangements for pharmaceutical products distributed through established wholesaler networks or direct manufacturer channels, with compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and FDA registration.

State procurement offices and health agencies are the primary issuing bodies, with the Minnesota Department of Administration (administering the multi-state MMCAP cooperative), the Texas Health and Human Services Commission, and Seminole County, Florida representing recent activity. The geographic spread includes Minnesota, Texas, and Florida, with MMCAP extending coverage to Oregon through cooperative purchasing. Representative recent opportunities include Minnesota's MMCAP RFP (due March 26, 2026) for generic multi-source pharmaceutical supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and contract terms through June 30, 2028; the Texas HHS Commission's RFI (response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM arrangements; and Seminole County's IFB (response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The code shows limited recent activity narrowly aligned to fluoxetine procurement itself; opportunities reflect pharmaceutical category-level contracting rather than single-drug sourcing.